Bayer AG Sponsored ADR (BAYRY)
Why Bayer's Worst Years Might Be The Start Of Its Comeback
Bayer Aktiengesellschaft remains deeply undervalued despite ongoing business struggles and litigation headwinds, with significant upside potential if challenges are resolved. Bayer's Q2 '25 results were mediocre, but the company raised 2025 guidance and is making progress on litigation settlements, aiming for containment by the end of 2026. The turnaround strategy includes workforce reductions, deleveraging, and new product launches, but core segments still face sales and profit pressures, especially in Crop Science and Pharma.
Bayer Reports Positive Data on Cell Therapy for Parkinson's Disease
BAYRY's subsidiary BlueRock reports 36-month data showing its Parkinson's therapy bemdaneprocel remains safe and effective in easing motor symptoms.
Focus: Parkinson's disease at forefront of Bayer bet on cell and gene therapies
Bayer's pioneering cell and gene therapies for Parkinson's disease are at the forefront of an exciting but risky test of CEO Bill Anderson's development credentials as patent expiries on blockbuster drugs threaten the group's long-term growth projects.
Are Investors Undervaluing Bayer (BAYRY) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Bayer, Kumquat Biosciences Team Up on New Potential Cancer Drug
Under the global exclusive license deal, Kumquat will be responsible for the Phase 1a study of its inhibitor and Bayer will take the drug to market.
Bayer Beats on Q2 Earnings and Sales, Raises '25 Adjusted Sales View
BAYRY beats on Q2 earnings and raises 2025 sales outlook (on a currency-adjusted basis) as pharma growth offsets currency and Xarelto headwinds.
Bayer says it has cut 12,000 jobs so far under restructuring push
Bayer said on Wednesday it had cut about 12,000 full-time positions since the start of a restructuring programme to speed up decision-making and reduce managerial and administrative positions.
Bayer Stock Is Soaring Ahead Of Its Earnings Release
Bayer Aktiengesellschaft raised its 2025 sales and earnings guidance, reflecting improved performance in its pharmaceuticals division and better-than-expected results. Litigation risks have eased significantly, with major Roundup settlements reducing future legal expenses and enhancing financial visibility. Despite a still-challenged balance sheet and negative net income margin, profitability is expected to improve as litigation costs decline.
Best Value Stocks to Buy for July 22nd
OPRT, BAYRY and SHG made it to the Zacks Rank #1 (Strong Buy) value stocks list on July 22, 2025.
New Strong Buy Stocks for July 22nd
BTG, PGR, BAYRY, BCH and LNW have been added to the Zacks Rank #1 (Strong Buy) List on July 22, 2025.
BAYRY Skyrockets 62.9% YTD: Should You Buy or Sell the Stock?
Bayer's shares are up 62.9% YTD as new drug approvals and a streamlined model fuel a sharp pharma turnaround.
Bayer: Upside Compelling - Buy
Bayer is a deep contrarian play, trading at less than 6x P/E, with potential for 100%+ upside if litigation risks subside. The main risks are ongoing glyphosate litigation and pharma pricing pressures, but current valuation heavily discounts these concerns. Despite crop science headwinds and legacy litigation, core pharma brands and pipeline growth provide a foundation for recovery.
